MID ATLANTIC RETINA

EYP-1901 Shows Promising Results in VERONA Trial for Diabetic Macular Edema

- EYP-1901, a novel treatment containing varolanib in a bio-erodible polymer, outperformed aflibercept in vision improvement and disease control for diabetic macular edema in the VERONA trial. - The treatment demonstrated exceptional durability, with most patients not requiring supplemental anti-VEGF therapy for 6 months, potentially reducing treatment burden for patients with sight-threatening retinal conditions. - Dr. Carl Regillo, Director of Retina Service at Wills Eye Hospital, highlighted the significance of this innovation in addressing current limitations in retinal treatments, including high treatment burdens and challenges in patient engagement.